Jun 01, 2019 2:15pm EDT IMV Inc. Presents New Positive Data from Phase 2 Monotherapy Arm of Its Decide1 Trial in Advanced Ovarian Cancer and Continued Duration of Clinical Benefits to Patients with Progression Free Survival
May 16, 2019 7:05am EDT IMV to Present New Data at 2019 ASCO Annual Meeting From Its Phase 2 Clinical Trial Evaluating DPX-Survivac in Ovarian Cancer
May 08, 2019 7:05am EDT IMV Joins World Ovarian Cancer Coalition and Ovarian Cancer Canada in Supporting Ovarian Cancer Day 2019
May 03, 2019 7:05am EDT IMV to Provide Updated Data From Phase 2 Study Evaluating DPX-Survivac in Combination with Merck’s Keytruda® in DLBCL
Apr 26, 2019 7:05am EDT IMV Inc. to Announce First Quarter 2019 Results and Host a Conference Call and Webcast on May 10, 2019
Apr 18, 2019 7:05am EDT IMV to Provide Updated Clinical Data at 2019 ASCO Annual Meeting on Lead Candidate DPX-Survivac in Ovarian Cancer and Other Solid Tumors
Apr 16, 2019 9:31am EDT IMV Inc. Issues Statement on Recent Market Activity And Provides Corporate Update
